Navigation Links
New clinical trial to test novel approach to treat triple-negative breast cancer
Date:6/2/2011

motherapy is currently the only drug treatment option, and it has a lot of side effects compared to hormone therapies like anastrozole."

Triple-negative breast cancer is unique in that it lacks three common receptors in the cell estrogen, progesterone or human epidermal growth factor 2 (HER2), which are the targets of drugs widely used today to treat breast cancer. As a result, this cancer can be very difficult to treat; it doesn't respond to therapies that target estrogen and progesterone receptors, such as tamoxifen (Nolvadex), fulvestrant (Faslodex) and aromatase inhibitors (Femara, Arimidex and Aromasin), or to HER2-targeted therapies such as trastuzumab (Herceptin) and lapatinib (Tykerb).

About 15 to 20 percent of breast cancers are triple-negative. For unknown reasons, there is a higher prevalence of this type of breast cancer among African-Americans, young women and women with the BRCA1 gene mutation. African-American women are twice as likely as white women to have this type of cancer, which can be very aggressive and spread to other parts of the body, such as the lungs, liver and brain.

The clinical trial is based on laboratory studies by Dr. Brodie, a professor of pharmacology and experimental therapeutics, and Gauri J. Sabnis, Ph.D., an assistant professor of pharmacology and experimental therapeutics, at the University of Maryland School of Medicine, in collaboration with Saraswati Sukumar, M.S., Ph.D., a professor of oncology and pathology at the Johns Hopkins University School of Medicine. Their research showed that entinostat can sensitize triple-negative breast cancer cells to treatment with an aromatase inhibitor, and when combined with an aromatase inhibitor, also reduce the growth and spread of tumors in animal models.

"Adding to her long list of remarkable achievements, Dr. Brodie has continued her research into aromatase inhibitors, searching for ways to overcome tumors' resistance to treatment," says E. Alb
'/>"/>

Contact: Karen E. Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. The use of placebo in rheumatoid arthritis clinical trials may negatively impact patients
2. Clinical study suggests estrogen levels and breast health can be altered
3. Progress toward the clinical application of autologous induced pluripotent stem cells and gene repair therapy for treatment of familial hypercholesterolemia
4. New cancer drug discovered at U-M heads to clinical trials
5. JAMIA: Evaluating clinical information systems, patients who use PHRs, how clinicians use EHRs
6. Preview of oral presentations at the 1st IOF-ESCEO Pre-Clinical Symposium
7. Press registration open for clinical nutrition conference
8. Clinical Benefits of Zimmers DeNovo® NT Natural Tissue Graft in First Surgery Documented in Peer-Reviewed Publication
9. Media alert: ACMG 2011 Clinical Genetics Meeting -- press registration is now open
10. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
11. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New clinical trial to test novel approach to treat triple-negative breast cancer
(Date:7/21/2015)... July 21, 2015 Today, ZTE announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... leading smartphone manufacturer in China and we ... 02 5 for Axon , ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... York City/Great Neck, NY) The Brain & Behavior ... Research on Schizophrenia and Depression) has announced approximately $4 ... has invested close to $300 million in research to ... for mental illness. From about 500 applicants, forty ...
... pathogen that causes Lyme Diseaseunlike any other known organismcan ... needs to make proteins and enzymes. Instead of iron, ... thus eluding immune system defenses that protect the body ... Borrelia burgdorferi requires unusually high levels of ...
... researchers have taken an important step in the ongoing battle ... a breakthrough device that can immediately detect the presence of ... lighter than a cellphone and about the size of a ... measure nicotine in the air. A sensor chip then records ...
Cached Biology News:Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 2Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 3Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 4Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 5Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 6Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 7Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 8Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 9Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 10Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 11Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 12Scientists reveal quirky feature of Lyme disease bacteria 2Scientists reveal quirky feature of Lyme disease bacteria 3Scientists create new tools for battling secondhand smoke 2Scientists create new tools for battling secondhand smoke 3
(Date:8/3/2015)... --  Intrexon Corporation (NYSE: XON ) today ... 2015 financial results after the market closes on Monday, ... a conference call at 5:30 PM ET to discuss ... The conference call may be accessed by dialing ... join the "Intrexon Corporation Call."  Participants may also access ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation introduces the compact, ... of analytical laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an ... and maintenance-free solution for a broad range of vacuum filtration applications. , Featuring ...
(Date:7/31/2015)... KONG , July 31, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... the U.S. Securities and Exchange Commission. The filed Form ... ended March 31, 2015. The Form 20-F can be ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
Breaking Biology Technology:Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Sterlitech Launches New Line of Vacuum Pumps 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4
... ATLANTA, May 1 CryoLife, Inc., (NYSE: ... company, announced today,that Harvey Morgan has been elected ... Morgan is a Managing Director at Bentley,Associates L.P., ... more than 35 years of investment banking experience ...
... 1 /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin ... leading manufacturer and distributor in China of ... medical industry and,glucose and starch products for ... appointment of Ms. Melody Shi as its ...
... Therapeutics (Amex:,CXM) announced today that Richard A. Schatz, M.D., ... early pioneer of coronary stent,technology and is best known ... Palmaz-Schatz stent. Dr. Schatz is Research Director of,Cardiovascular Interventions ... in La Jolla, California. He is also active in ...
Cached Biology Technology:Harvey Morgan Joins CryoLife Board of Directors 2Shengtai Pharmaceutical, Inc. Appoints New CFO 2Shengtai Pharmaceutical, Inc. Appoints New CFO 3Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board 2Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board 3Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board 4
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: